CN101535281A - 3-苄基-2-甲基-2，3，3a，4，5，6，7，7a-八氢苯并[d]异噁唑-4-酮的盐 - Google Patents

3-苄基-2-甲基-2，3，3a，4，5，6，7，7a-八氢苯并[d]异噁唑-4-酮的盐 Download PDF

Info

Publication number
CN101535281A
CN101535281A CNA2007800406598A CN200780040659A CN101535281A CN 101535281 A CN101535281 A CN 101535281A CN A2007800406598 A CNA2007800406598 A CN A2007800406598A CN 200780040659 A CN200780040659 A CN 200780040659A CN 101535281 A CN101535281 A CN 101535281A
Authority
CN
China
Prior art keywords
fumarate
formula
medicine
compound
purposes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800406598A
Other languages
English (en)
Chinese (zh)
Inventor
法比欧·纳加尼
劳拉·迪尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abiogen Pharma SRL
Original Assignee
Abiogen Pharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abiogen Pharma SRL filed Critical Abiogen Pharma SRL
Publication of CN101535281A publication Critical patent/CN101535281A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNA2007800406598A 2006-11-02 2007-10-31 3-苄基-2-甲基-2，3，3a，4，5，6，7，7a-八氢苯并[d]异噁唑-4-酮的盐 Pending CN101535281A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI2006A002102 2006-11-02
IT002102A ITMI20062102A1 (it) 2006-11-02 2006-11-02 Nuovui sali di 3-benzil-2-metil-2,3,3a,4,5,6,7,7a-ottaidrobenzo-d-isossazol-4-one

Publications (1)

Publication Number Publication Date
CN101535281A true CN101535281A (zh) 2009-09-16

Family

ID=39145485

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2007800406598A Pending CN101535281A (zh) 2006-11-02 2007-10-31 3-苄基-2-甲基-2，3，3a，4，5，6，7，7a-八氢苯并[d]异噁唑-4-酮的盐
CNA2007800406691A Pending CN101535282A (zh) 2006-11-02 2007-10-31 3-苄基-2-甲基-2，3，3a，4，5，6，7，7a-八氢苯并[d]异噁唑-4-酮的盐

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2007800406691A Pending CN101535282A (zh) 2006-11-02 2007-10-31 3-苄基-2-甲基-2，3，3a，4，5，6，7，7a-八氢苯并[d]异噁唑-4-酮的盐

Country Status (20)

Country Link
US (2) US20100069451A1 (https=)
EP (2) EP2094675B1 (https=)
JP (2) JP2010509310A (https=)
KR (2) KR20090077014A (https=)
CN (2) CN101535281A (https=)
AT (2) ATE502021T1 (https=)
AU (2) AU2007315832A1 (https=)
BR (2) BRPI0718392A2 (https=)
CA (2) CA2667513A1 (https=)
DE (2) DE602007013801D1 (https=)
HR (2) HRP20090470A2 (https=)
IL (2) IL198443A0 (https=)
IT (1) ITMI20062102A1 (https=)
MX (2) MX2009004294A (https=)
NO (2) NO20092114L (https=)
NZ (2) NZ577978A (https=)
RS (2) RS20090389A (https=)
RU (2) RU2009120724A (https=)
WO (2) WO2008053325A1 (https=)
ZA (2) ZA200903618B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2112142A1 (en) * 2008-04-24 2009-10-28 Abiogen Pharma S.p.A. Process for preparing a crystalline form compound of 3-benzyl-2-methyl-2,3,3a,4,5,6,7,7a-octahydrobenzo[d]isoxazol-4-one
ITMI20080768A1 (it) * 2008-04-24 2009-10-25 Abiogen Pharma Spa Procedimento per la preparazione di un composto in forma cristallina di 3-benzil-2-metil-2,3,3a,4,5,6,7,7a-ottaidro-benzo[d]isossazol-4-one
EP2218721A1 (en) * 2009-02-11 2010-08-18 LEK Pharmaceuticals d.d. Novel salts of sitagliptin
WO2011010332A1 (en) * 2009-07-23 2011-01-27 Abiogen Pharma S.P.A. Process for preparing rel-(3r*,3as*,7as*)-3-benzyl-2-methyl-2,3, 3a,4,5,6,7,7a- octahydrobenzo[d]isoxazoi-4-one or a salt thereof
US10131642B1 (en) * 2015-01-30 2018-11-20 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4161595A (en) * 1978-10-02 1979-07-17 Bristol-Myers Company Levulinic acid salt
US4419358A (en) * 1981-11-12 1983-12-06 Mead Johnson & Company Isethionic acid salt of 9-cyclohexyl-2-propoxy-9H-purine-6-amine and compositions containing an effective bronchodilating concentration of it
GB2264299B (en) * 1992-02-19 1995-07-26 British Tech Group Iso-oxazolidine derivatives

Also Published As

Publication number Publication date
EP2094675A1 (en) 2009-09-02
WO2008053326A1 (en) 2008-05-08
NZ577311A (en) 2010-10-29
KR20090082452A (ko) 2009-07-30
NO20092114L (no) 2009-05-29
IL198443A0 (en) 2010-02-17
HRP20090477A2 (hr) 2009-11-30
EP2094674A1 (en) 2009-09-02
JP2010509309A (ja) 2010-03-25
US20100069451A1 (en) 2010-03-18
MX2009004293A (es) 2009-05-08
ATE504578T1 (de) 2011-04-15
ZA200903810B (en) 2010-07-28
RU2009120724A (ru) 2010-12-10
AU2007315833A1 (en) 2008-05-08
US20100069450A1 (en) 2010-03-18
ZA200903618B (en) 2010-07-28
JP2010509310A (ja) 2010-03-25
RU2009120667A (ru) 2010-12-10
RS20090389A (sr) 2010-12-31
NZ577978A (en) 2010-10-29
CN101535282A (zh) 2009-09-16
AU2007315832A1 (en) 2008-05-08
BRPI0718392A2 (pt) 2013-11-26
IL198444A0 (en) 2010-02-17
DE602007013278D1 (de) 2011-04-28
NO20092115L (no) 2009-05-29
CA2667515A1 (en) 2008-05-08
CA2667513A1 (en) 2008-05-08
HRP20090470A2 (hr) 2009-11-30
EP2094675B1 (en) 2011-04-06
DE602007013801D1 (de) 2011-05-19
EP2094674B1 (en) 2011-03-16
ATE502021T1 (de) 2011-04-15
MX2009004294A (es) 2009-05-08
WO2008053325A1 (en) 2008-05-08
BRPI0718391A2 (pt) 2013-11-26
RS20090388A (sr) 2010-12-31
ITMI20062102A1 (it) 2008-05-03
KR20090077014A (ko) 2009-07-13

Similar Documents

Publication Publication Date Title
KR101644657B1 (ko) 고체 형태의 (ｓ)-에틸 2-아미노-3-(4-(2-아미노-6-((ｒ)-1-(4-클로로-2-(3-메틸-1ｈ-피라졸-1-일)페닐)-2,2,2-트리플루오로에톡시)-피리미딘-4-일)페닐)프로파노에이트
EP0506532A1 (fr) Nouveaux dérivés de l'indole, procédé de préparation et médicaments les contenant
RU2760558C2 (ru) Целевой лекарственный препарат и новые композиции, комбинации на его основе и способы их применения
OA12165A (fr) Dérivés aminés de dihydro-1,3,5-triazine et leurs applications en thérapeutique.
CN101535281A (zh) 3-苄基-2-甲基-2，3，3a，4，5，6，7，7a-八氢苯并[d]异噁唑-4-酮的盐
EP0015038B1 (fr) Composition pharmaceutique comprenant un dérivé de diphénylhydantoine, dérivés mis en oeuvre et leur préparation
JPWO2009096455A1 (ja) 脂肪性肝疾患の治療用医薬組成物
EP0446141A1 (fr) Nouveaux dérivés d'imidazo [1,2-C] quinazoline leur procédé de préparation et les compositions pharmaceutiques les renfermant
FR2776660A1 (fr) Diazepino-indoles de phosphodiesterases iv
FR2822464A1 (fr) Derives biguanides et leurs applications en therapeutique
CA2898450A1 (en) Isometheptene isomer
JP6279773B2 (ja) ロイコトリエン受容体拮抗薬として用いるシクロプロピル不飽和キノリン化合物及びその使用
KR20110074574A (ko) 1-부틸-2-히드록시아르알킬 피페라진 유도체 및 항-우울증제로서의 그 용도
EP2931266B1 (fr) Composition et kit comprenant des dérivés de pipérazine et de la metformine, leur utilisation dans le traitement du diabète
EP2497774A1 (fr) Dérivés de dihydro-oxazolobenzodiazépinone, procédés de leur préparation et compositions pharmaceutiques contenant ces composés
OA13294A (fr) Molécules duales contenant un dérivé peroxydique, leur synthèse et leurs applications thérapeutiques.
CN100356923C (zh) S－10－羟基－10,11－二氢－卡马西平在制备药物组合物中的用途
WO2018083247A1 (en) 4,4a,5,7-tetrahydro-3h-furo[3,4-b]pyridinyl compounds
EP0311467A2 (fr) Utilisation de dérivés de pyrrolo[3,2,1-hi]indole pour obtenir un médicament destiné au traitement du diabète
JP2000053620A (ja) 芳香族抗真菌剤
EP0263020A1 (fr) Dérivés de 4-phénylthiazole

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090916